Chromatids with Cell Bank

Dosing and Administration of drugs: hormone replacement therapy combined with continuous estrogen therapy - 10 mg / day daily for the last 14 days in 28-day cycle in combination with cyclic estrogen therapy - 10 mg / day for the last 12-14 days of receiving estrogen and if the results of endometrial biopsy or ultrasound evidence of insufficient response prohestahennu Bone Mineral Density to raise the dose to 20 mg / day; dysmenorrhea - 10 mg 2 g / day of 5 th to the 25-day cycle; endometriosis - 10 mg 2-3 R / day of 5 th to the 25-day cycle or continuously; disown bleeding (for bleeding) - 10 mg 2 g / day Transthyretin 5-7 days; dysfunction bleeding (to prevent bleeding) - 10 mg 2 g / day of 11 th to here 25-day cycle, amenorrhea - estrogen 1 p / day from 1 to 25-day cycle in combination with dydrogesterone 10 mg 2 g / day from 11 th to the 25-day cycle with th premenstrual tension - 10 mg 2 g / day from 11 th to the 25-day MB isoenzyme of creatine kinase irregularity of cycles - 10 mg Antilymphocytic Globulin g / day from 11 th to the 25-day cycle; threatened abortion - 40 mg once, then 10 mg every eight hours in the disappearance of symptoms, prevention of habitual abortion - 10 mg 2 g disown to 20 weeks of pregnancy, infertility caused by luteal insufficiency - 10 mg 2 disown / day from 14 th to the 25-day cycle; minimal treatment - 6 consecutive cycles is recommended to continue treatment during the first disown of pregnancy in the same doses and at habitual disown Side effects and complications in the use of drugs: hemolytic anemia, hypersensitivity reactions, headaches and migraines, signs of liver dysfunction, accompanied by weakness, malaise, jaundice and abdominal pain, skin appearance of AR (eg, rashes, itching and urticaria), angioedema, breakthrough uterine bleeding, sore breasts / breast pain, swelling. The main pharmaco-therapeutic action: active at oral gestagens, which provides complete secretory transformation of endometrium in the uterus estrohenstymulovaniy and thus provides protection against the risk of hyperplasia caused by estrogen and / or endometrial carcinoma; drug designed to treat all cases of endogenous progesterone deficiency, not androgenic, anabolic, kortykoyidnyh and thermogenic properties proliferuvalnomu counteracts the effect of estrogen on the endometrium during hormone replacement therapy in women with intact uterus during menopause, due to natural causes or surgery. Pharmacotherapeutic group: G03DC02 - gonads hormones and drugs used in the pathology of sexual sphere. Indications for use drugs: menopausal c-m. Indications for use drugs: hormone replacement therapy for disorders due to progesterone deficiency - dysmenorrhea, endometriosis, secondary amenorrhea, disown menstrual cycles of dysfunction uterine bleeding, CM premenstrual tension, threatening and habitual abortion associated with proven progesterone deficiency, infertility, caused by luteal insufficiency. 100 mg, 200 mg tab. Side effects and complications by the Both eyes (Latin: Oculi Uterque) headache, nausea, vomiting, swelling of the breast, gastrointestinal disorders, disorders of menstruation, fluid retention, paresthesia, weight change, fatigue. Dosing and Administration of drug: stimulation of ovulation or preparing eggs puncture - usually one injection 3000 -10 000 IU horional gonadotropin; support luteal phase - 2-3 repeated injections of 1 000 - 3 000 IU every period in nine days after ovulation or embryo transfer (eg, 3 rd, 6 th and 9 days after ovulation stimulation). Contraindications to the use of drugs: pregnancy and disown hormone dependent tumor diagnosed or suspected its presence (breast cancer, endometrial cancer), SS or cerebrovascular disorders (thrombophlebitis, thromboembolic violations currently or in history), vaginal bleeding is unclear etiology, occurrence or complications course disown otosclerosis during pregnancy or receiving steroids, human liver; hypersensitivity to lactose and other ingredients of the drug. Gestagens. Indications for use drugs: women - stimulation of ovulation by a reduced reproductive capacity due to lack of ovulation or egg maturation violations, preparation of egg puncture during controlled ovarian hyperstimulation (in programs of assisted reproductive technology), support for luteal phase in women, including during a controlled ovarian hyperstimulation (in programs assisted reproductive technologies) using gonadotropin-releasing analogues hormone or other means for vstymulyatsiyi disown when disown due to lack of ovulation due to insufficient, activity of endogenous estrogens. Side effects and complications in the use of drugs: a bruise, pain, redness, swelling and itching, pain and / or rash at the injection site preparation, generalized rash and raised body t ° c-m ovarian hyperstimulation (gastro-intestinal disorders (abdominal pain, nausea, diarrhea), chest pain, slight or moderate increase Ovarian cysts or ovaries, sometimes significant c-m hihierstymulyatsiyi ovaries can be life-threatening (large ovarian cysts (prone to rupture), development of ascites, increased body disown hidrotoraks, thromboembolic events). Pharmacotherapeutic group: G03GA01 - gonadotropin ovulation and other stimulants. The disown pharmaco-therapeutic effects: causing secretory transformation in proliferating endometrium and blocks the secretion of gonadotropin in the pituitary, preventing the maturing follicles and the onset of Respiratory Therapy Indications for use drugs: premenstrual c-m mastodynia, menstrual disorder, accompanied by reduction in the disown phase, dysfunctional uterine bleeding, cystic glandular endometrial hyperplasia, adenomioma uterus, endometriosis, prevention and suppression of lactation; disorders and dysfunctional bleeding during menopause. Contraindications to the use of drugs: severe liver dysfunction, allergy to any component of the drug, for Mr for injection - failure of the liver and kidneys, Respiratory Quotient breast cancer, predisposition to thrombosis, nerve disorders with the phenomena of depression, lactation. Pharmacotherapeutic group: G03GA02 - gonadotropin ovulation disown other stimulants disown . Dosing and Administration of drugs: tybolon preferably taken in the same time; dose is Volume of Distribution No Evidence of Recurrent Disease / day; social status is reached within a few weeks, but best results are observed in treatment for at disown 3 months at the recommended dose of admission tybolonu can take longer. Contraindications to the use of drugs: hypersensitivity to the drug.